Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focused on cancer therapies - Says final sequences have been selected for its second programme BVX002, an antibody drug.
Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia.
The.
Bivictrix Therapeutics PLC on Wednesday said it has been granted a US patent for lead asset BVX001.
The Macclesfield, England-based biotechnology company focusing on cancer therapies said the.
Bivictrix Therapeutics PLC on Wednesday said it has raised GBP2.1 million through a placing and subscription of 16.4 million shares.
Earlier on Wednesday, the Macclesfield, England-based.
UPDATE: Bivictrix Therapeutics raises GBP2.1 million through fundraise lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.